Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting

   Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at
           American Diabetes Association Annual Scientific Meeting

PR Newswire

SAN DIEGO, June 20, 2013

SAN DIEGO, June 20, 2013 /PRNewswire/ --Orexigen^® Therapeutics, Inc.
(Nasdaq: OREX) a biopharmaceutical company focused on the treatment of
obesity, today announced the schedule of its upcoming Contrave^® (naltrexone
sustained release (SR) /bupropion SR) clinical data presentations taking place
at the American Diabetes Association (ADA) 73rd Scientific Sessions, June
21-25, 2013.

ADA: McCormick Place Convention Center (West Building), Chicago, IL

Abstract# 1056-P – "Combination Naltrexone/Bupropion Therapy Resulted in
Clinically Meaningful Improvements in Weight and Quality of Life - Integrated
Analysis of Four Phase 3 Trials"
Lead Author: Ronette L. Kolotkin

Abstract# 1130-P – "An Integrated Analysis of Weight Loss with Combination
Naltrexone/Bupropion Therapy by BMI (Obesity) Classification"
Lead Author: Caroline M. Apovian

Abstract# 1149-P – "Early Improvement in Control of Eating Is Associated with
Long-term Weight Loss - Integrated Analysis of Four Phase 3 Trials of
Combination Naltrexone/Bupropion Treatment"
Lead Author: Ken Fujioka

All abstracts will be presented at General Poster Session 2, on Sunday, June
23, from 12:00 PM - 2:00 PM, in Hall F1 – Posters.

Abstract #1056-P will also be showcased in a Guided Audio Poster Tour at the
Innovative Oral Agents–Innovative Discoveries session on Monday, June 24, from
1:00 PM - 2:00 PM.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the
treatment of obesity. The Company's lead product candidate is Contrave®, which
has completed Phase 3 clinical trials and for which a New Drug Application has
been submitted and reviewed by the FDA. The Company has also reached agreement
with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the
Contrave cardiovascular outcomes trial. The Company's other product candidate,
Empatic™, has completed Phase 2 clinical trials. Further information about the
Company can be found at www.orexigen.com.

Orexigen Contact:                                     Media Contact:
McDavid Stilwell                                      Denise Powell
VP, Corporate Communications and Business Development BrewLife
(858) 875-8629                                        (510) 703-9491

SOURCE Orexigen Therapeutics, Inc.

Website: http://www.orexigen.com
 
Press spacebar to pause and continue. Press esc to stop.